Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Share-based Compensation (2020 - 2025)

GeneDx Holdings has reported Share-based Compensation over the past 6 years, most recently at $9.8 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $9.8 million for Q4 2025, up 243.76% from a year ago — trailing twelve months through Dec 2025 was $32.2 million (up 251.96% YoY), and the annual figure for FY2025 was $32.2 million, up 251.96%.
  • Share-based Compensation for Q4 2025 was $9.8 million at GeneDx Holdings, down from $10.6 million in the prior quarter.
  • Over the last five years, Share-based Compensation for WGSWW hit a ceiling of $165.0 million in Q1 2021 and a floor of -$912000.0 in Q4 2023.
  • Median Share-based Compensation over the past 5 years was $3.4 million (2024), compared with a mean of $15.1 million.
  • Biggest five-year swings in Share-based Compensation: soared 4477.84% in 2022 and later plummeted 1039.58% in 2024.
  • GeneDx Holdings' Share-based Compensation stood at $37.0 million in 2021, then tumbled by 98.86% to $422000.0 in 2022, then tumbled by 316.11% to -$912000.0 in 2023, then soared by 411.95% to $2.8 million in 2024, then soared by 243.76% to $9.8 million in 2025.
  • The last three reported values for Share-based Compensation were $9.8 million (Q4 2025), $10.6 million (Q3 2025), and $7.8 million (Q2 2025) per Business Quant data.